Pharmaceuticals News and Research

RSS

Viewpoints: Concerns that AIDS fight is losing steam; Pharmacy choice bill is praised; Texas sex-ed policies questioned

The considerable progress in recent years - including the 22-fold increase in the number of people receiving anti-retroviral drugs between 2001-2010 - has been due to scientific breakthroughs and to civil society's efforts to keep AIDS on the political agenda. This is now changing.

23 Sep 2011

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the therapeutic indication for Soliris® (eculizumab) be extended to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS) in Europe.

23 Sep 2011

Gilead announces EMA CHMP positive opinion for HIV-1 drug, Eviplera

Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera.

23 Sep 2011

Synthetic lectins inhibit HIV from entering cells

University of Utah researchers have discovered a new class of compounds that stick to the sugary coating of the AIDS virus and inhibit it from infecting cells - an early step toward a new treatment to prevent sexual transmission of the virus.

23 Sep 2011

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

Astellas Pharma Europe Ltd. (APEL) and Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhoea (CDAD).

23 Sep 2011

Momenta, Sandoz file patent suit against Amphastar and Watson over Enoxaparin Sodium Injection

Watson Pharmaceuticals, Inc. today confirmed that Momenta Pharmaceuticals, Inc. and Sandoz Inc. have filed suit against Amphastar Pharmaceuticals, Inc. and Watson on September 21, 2011 in the United States District Court for the District of Massachusetts.

23 Sep 2011

Commercial interests confound fight against NCDs, some experts say

The Washington Post examines the influence of commercial interests on the "political declaration" that emerged from this week's U.N. High-level Meeting on Non-Communicable Diseases (NCDs) in New York. NCDs "are the globe's biggest health problem, responsible for 63 percent of all deaths each year, with incidence growing steeply in the low-income, rapidly urbanizing nations of the world," but they "are deeply entangled with important global industries, not only tobacco but also food, pharmaceuticals, advertising, transportation and construction," the newspaper writes.

23 Sep 2011

CoPlex, Hawthorn sign license agreement for hawAD14 Alzheimer's drug

CoPlex Therapeutics has signed an exclusive global license agreement with Hawthorn Pharmaceuticals to develop and commercialize hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer's and other neurodegenerative diseases.

23 Sep 2011

New microbicide may block AIDS virus from infecting cells

23 Sep 2011

Adamis receives patents for APC-200 prostate cancer drug in South Africa, Singapore

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes its compound APC-200 was recently granted patents in Singapore and South Africa. These patents significantly strengthen the Adamis APC-200 patent portfolio for the use of APC-200 in the treatment of early and late stage prostate cancer.

23 Sep 2011

Shire announces update on approval status and availability of ProAmatine SOH drug

Shire plc, the global specialty biopharmaceutical company, announces an update on the approval status and availability of ProAmatine (midodrine HCl), a medicine approved for the treatment of symptomatic orthostatic hypotension.

23 Sep 2011

Viewpoints: Ron Paul, USA Today on individual mandate; NYT's Greenhouse on court challenges to health law

Massachusetts leads the nation in health insurance coverage of its citizens, and Texas is dead last. You'd think that former Massachusetts governor Mitt Romney would be bragging about his role in making his state No. 1, and that Texas Gov. Rick Perry would be embarrassed by how poorly his state is doing. But that's not how the script is playing out … That's odd, though, because the mandate was born as a conservative response to President Clinton's much maligned health reform proposal.

23 Sep 2011

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

Acetylon Pharmaceuticals today announced the initiation of patient treatments in a three-part Phase 1-2a clinical trial of ACY-1215, an oral Class II histone deacetylase (HDAC) inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

22 Sep 2011

ACT receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt's Macular Dystrophy

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare products Regulatory Agency to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt's Macular Dystrophy using retinal pigment epithelium (RPE) derived from human embryonic stem cells.

22 Sep 2011

Palatin's fourth quarter net loss decreases to $3.3 million

Palatin Technologies, Inc., a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.

22 Sep 2011

Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC

Patients at Virginia G. Piper Cancer Center Clinical Trials are the first in the nation to participate in a clinical trial to determine the safety, tolerability and preliminary activity of an investigational drug that targets cell-signaling proteins associated with the most common form of lung cancer, as well as other forms of cancer such as lymphomas and neuroblastoma.

22 Sep 2011

OPTOS to acquire ophthalmic instrumentation business from OPKO

OPKO Health, Inc. has agreed to sell its ophthalmic instrumentation business to OPTOS, Inc., a subsidiary of Optos plc, a leading and rapidly growing medical technology company engaged in the design, development, manufacture and marketing of devices to image the retina of the eye. Optos will pay OPKO $17.5 million in cash at closing, plus future royalties.

22 Sep 2011

First epidemiological study on the prevention of Alzheimer's disease

Researchers at the Douglas Mental Health University Institute, in Montreal, Quebec, are about to launch the first epidemiological study on the prevention of Alzheimer's disease.

22 Sep 2011

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine.

22 Sep 2011

S-equol improve appearance of crow's feet skin wrinkles in Japanese menopausal women

A soy germ-based nutritional supplement containing Natural S-equol significantly improved the appearance of crow's feet skin wrinkles of the outer corner of the eyes in Japanese menopausal women, suggesting that supplements containing Natural S-equol have potential to slow skin aging, according to data from a controlled pilot study simultaneously published online in the peer-review journal Menopause and presented in a poster session at the North American Menopause Society annual meeting.

22 Sep 2011

Pharmaceuticals News and Research

Viewpoints: Concerns that AIDS fight is losing steam; Pharmacy choice bill is praised; Texas sex-ed policies questioned

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

Gilead announces EMA CHMP positive opinion for HIV-1 drug, Eviplera

Synthetic lectins inhibit HIV from entering cells

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

Momenta, Sandoz file patent suit against Amphastar and Watson over Enoxaparin Sodium Injection

Commercial interests confound fight against NCDs, some experts say

CoPlex, Hawthorn sign license agreement for hawAD14 Alzheimer's drug

New microbicide may block AIDS virus from infecting cells

Adamis receives patents for APC-200 prostate cancer drug in South Africa, Singapore

Shire announces update on approval status and availability of ProAmatine SOH drug

Viewpoints: Ron Paul, USA Today on individual mandate; NYT's Greenhouse on court challenges to health law

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

ACT receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt's Macular Dystrophy

Palatin's fourth quarter net loss decreases to $3.3 million

Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC

OPTOS to acquire ophthalmic instrumentation business from OPKO

First epidemiological study on the prevention of Alzheimer's disease

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

S-equol improve appearance of crow's feet skin wrinkles in Japanese menopausal women

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence